IL-10 R alpha
IL-10 R alpha Molekülinformation
| Englischer Name | Interleukin 10 receptor | Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 9 | Target-Alias | Receptors， Interleukin-10 |
| Höchste Forschungs- und Entwicklungsphase | Phase 3 Clinical | ||
| Englischer Name | Interleukin 10 receptor |
| Target-Alias | Receptors， Interleukin-10 |
| Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 9 |
| Höchste Forschungs- und Entwicklungsphase | Phase 3 Clinical |
IL-10 R alpha Produktliste
- Attribut
Protein (4)
- Produktbibliothek
Online (4)
- Spezies
Human (2)Cynomolgus (1)Mouse (1)
- Etikett
Fc Tag & Avi Tag (1)Fc Tag (3)
- Marker
Biotin-labeled (1)Unconjugated (3)
| Produktnummer | Spezies | Expressionssystem | Produktbeschreibung | Proteinstruktur | Reinheit | Eigenschaften | Vorbestellen/Bestellen |
|---|---|---|---|---|---|---|---|
 Human | HEK293 | Biotinylated Human IL-10 R alpha / CD210 Protein, Fc,Avitag™ (MALS verified) |  |  |  |  In den Warenkorb legen | |
 Mouse | HEK293 | Mouse IL-10 R alpha / CD210 Protein, Fc Tag |  | | | In den Warenkorb legen | |
 Cynomolgus | HEK293 | Cynomolgus IL-10 R alpha / CD210 Protein, Fc Tag |  | | | In den Warenkorb legen | |
| Human | HEK293 | Human IL-10 R alpha / CD210 Protein, Fc Tag (MALS verified) |  | | | In den Warenkorb legen |
Gesamtmenge4
- 1
IL-10 R alpha Molekülhintergrund
Interleukin-10 receptor subunit alpha (IL-10 R alpha ) is a cell surface receptor for the cytokine IL-10 that participates in IL-10 mediated anti-inflammatory functions, limiting excessive tissue disruption caused by inflammation. Upon binding to IL10, induces a conformational change in IL10RB, allowing IL10RB to bind IL10 as well.In turn, the heterotetrameric assembly complex, composed of two subunits of IL10RA and IL10RB, activates the kinases JAK1 and TYK2 that are constitutively associated with IL10RA and IL10RB respectively.These kinases then phosphorylate specific tyrosine residues in the intracellular domain in IL10RA leading to the recruitment and subsequent phosphorylation of STAT3
IL-10 R alpha Molekülalias
Interleukin-10 receptor subunit alpha,IL-10 receptor subunit alpha,IL-10R subunit alpha,IL-10RA,CDw210a,Interleukin-10 receptor subunit 1,IL-10R subunit 1,IL-10R1,CD210,IL10RA,IL10R
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| IAE-0972 | IAE-0972 | Phase 3 Clinical | SunHo (China) BioPharmaceutical Co Ltd | Carcinoma, Basosquamous; Carcinoma, Hepatocellular; Colorectal Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| Recombinant anti-human EGFR antibody/IL-10 bispecific Fc fusion protein(Dingfu Biotarget) | CmAb-(IL10)2; DF203; DF-203 | Phase 2 Clinical | Dingfu Biotarget Co Ltd | Ascites; Pleural Effusion, Malignant; Solid tumours | Details |
| AG-019 | AG-019 | Phase 2 Clinical | Precigen Actobio Inc | Diabetes Mellitus, Type 1 | Details |
| Meta 10C-IL-10 TILs | Meta10-TIL; Meta 10C-IL-10 TILs | Phase 2 Clinical | Leman Biotech Co Ltd | Neoplasms; Solid tumours | Details |
| IBB-0979 | IBB0979; IBB-0979 | Phase 2 Clinical | SunHo (China) BioPharmaceutical Co Ltd | Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Neoplasms; Peritoneal Neoplasms; Small Cell Lung Carcinoma; Solid tumours | Details |
| Vimekofusp | AMT-101 (Applied Molecular Transport) | Phase 2 Clinical | Applied Molecular Transport | Colitis, Ulcerative | Details |
| F8-IL10 | F8-IL10; PF-06687234 | Phase 2 Clinical | Philogen Spa | Arthritis, Rheumatoid; Colitis, Ulcerative; Inflammatory Bowel Diseases | Details |
| PEG-ilodecakin | AM-0010 | Phase 1 Clinical | Armo Biosciences, Merck Sharp & Dohme Corp | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Granulomatosis with Polyangiitis; Melanoma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Solid tumours; Vasculitis | Details |
| Diakine-DK2 10 (EGFR) | DK210; DK-2-10 | Phase 1 Clinical | Deka Biosciences Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Genital Neoplasms, Female; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms; Pancreatic Neoplasms; Skin Neoplasms; Solid tumours | Details |
- Molekülinformation
- Produktliste
- Klinische Arzneimittelinformation